Preferred Label : Anti-IL-4/IL-13 Combination Agent QBX258;
NCIt synonyms : VAK296/QAX576; VAK296 Plus QAX576; VAK694 Plus QAX576; VAK694/QAX576;
NCIt definition : A combination agent composed of the two human monoclonal antibodies VAK694 (VAK296),
targeting interleukin-4 (IL-4), and QAX576, targeting IL-13, that can potentially
be used to block signaling mediated by IL-4 and IL-13. Upon intravenous administration
of the anti-IL-4/IL-13 co,mbination agent QBX258, the two antibodies VAK694 and QAX576
target and block the activity of the two cytokines IL-4 and IL-13, respectively, which
prevents IL-4/IL-13-mediated signaling. In patients with breast cancer related lymphedema
(BCRL), this agent may prevent lymphedema-associated effects, such as fibrosis, hyperkeratosis,
the deposition of fibroadipose tissue, fluid accumulation, limb swelling, reduction
of skin elasticity, and pain. By reducing the excess volume, QBX258 may improve lymphatic
and arm functions. The development of lymphedema after lymphatic injury is associated
with tissue inflammation, the infiltration of CD4-positive cells and their differentiation
to the type 2 helper T-cell (Th2) phenotype. Th2 cells produce IL-4 and IL-13 that
play a key role in the development of lymphedema-associated symptoms as well as other
Th2-mediated diseases.;
Molecule name : QBX-258;
Origin ID : C122986;
UMLS CUI : C4053602;
Semantic type(s)
- concept_is_in_subset
- has_target
